Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ostrom, 2013, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010, Neuro Oncol., 15, ii1, 10.1093/neuonc/not151
Bonavia, 2011, Heterogeneity maintenance in glioblastoma: a social network, Cancer Res., 71, 4055, 10.1158/0008-5472.CAN-11-0153
Strupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med., 352, 987, 10.1056/NEJMoa043330
Furnari, 2007, Malignant astrocytic glioma: genetics, biology, and paths to treatment, Genes Dev., 21, 2683, 10.1101/gad.1596707
Gabrusiewicz, 2014, Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes, Oncotarget., 5, 2208, 10.18632/oncotarget.1893
Hermanson, 1992, Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops, Cancer Res., 52, 3213
Anzil, 1970, Glioblastoma multiforme with extracranial metastases in the absence of previous craniotomy. Case report, J Neurosurg., 33, 88, 10.3171/jns.1970.33.1.0088
Robert, 2008, Glioblastoma multiforme: a rare manifestation of extensive liver and bone metastases, Biomed Imag Interv J., 4, e3, 10.2349/biij.4.1.e3
Kanu, 2009, Glioblastoma multiforme: a review of therapeutic targets, Expert Opin Ther Targets., 13, 701, 10.1517/14728220902942348
Holland, 2000, Glioblastoma multiforme: the terminator, Proc Natl Acad Sci USA., 97, 6242, 10.1073/pnas.97.12.6242
Fujisawa, 2000, Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas, Lab Invest., 80, 65, 10.1038/labinvest.3780009
Maher, 2006, Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities, Cancer Res., 66, 11502, 10.1158/0008-5472.CAN-06-2072
van den Bent, 2010, Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective, Acta Neuropathol., 120, 297, 10.1007/s00401-010-0725-7
Wang, 2017, Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment, Cancer Cell., 32, 42, 10.1016/j.ccell.2017.06.003
2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385
Behnan, 2019, The landscape of the mesenchymal signature in brain tumours, Brain., 142, 847, 10.1093/brain/awz044
Behnan, 2017, Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency, Oncogene, 36, 570, 10.1038/onc.2016.230
Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell., 22, 425, 10.1016/j.ccr.2012.08.024
Gill, 2014, MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma, Proc Natl Acad Sci USA., 111, 12550, 10.1073/pnas.1405839111
Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell., 155, 462, 10.1016/j.cell.2013.09.034
Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell., 17, 98, 10.1016/j.ccr.2009.12.020
Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell., 9, 157, 10.1016/j.ccr.2006.02.019
Bhat, 2013, Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma, Cancer Cell., 24, 331, 10.1016/j.ccr.2013.08.001
Patel, 2014, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science., 344, 1396, 10.1126/science.1254257
Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell., 17, 510, 10.1016/S1040-1741(10)79529-4
de Souza, 2018, A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence, Cell Rep., 23, 637, 10.1016/j.celrep.2018.03.107
Reifenberger, 2017, Advances in the molecular genetics of gliomas - implications for classification and therapy, Nat Rev Clin Oncol., 14, 434, 10.1038/nrclinonc.2016.204
Waker, 2019, Brain tumors of glial origin, Adv Exp Med Biol., 1190, 281, 10.1007/978-981-32-9636-7_18
Singh, 2016, Post-translational modifications of OLIG2 regulate glioma invasion through TGF-β pathway, Cell Rep., 16, 950, 10.1016/j.celrep.2016.06.045
Fadhlullah, 2019, Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness, Oncogene., 38, 5367, 10.1038/s41388-019-0809-3
Daginakatte, 2007, Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth, Hum Mol Genet., 16, 1098, 10.1093/hmg/ddm059
Rutledge, 2013, Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class, Clin Cancer Res., 19, 4951, 10.1158/1078-0432.CCR-13-0551
Solga, 2015, RNA sequencing of tumor-associated microglia reveals Ccl5 as a stromal chemokine critical for neurofibromatosis-1 glioma growth, Neoplasia., 17, 776, 10.1016/j.neo.2015.10.002
Singh, 2012, Transforming fusions of FGFR and TACC genes in human glioblastoma, Science., 337, 1231, 10.1126/science.1220834
Radke, 2019, Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients, Acta Neuropathol Commun., 7, 89, 10.1186/s40478-019-0745-z
2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med., 343, 1350, 10.1056/NEJM200011093431901
Jesionek-Kupnicka, 2019, MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients, Arch Med Sci., 15, 504, 10.5114/aoms.2017.69374
ParvizHamidi, 2019, Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform, Biotechnol Appl Biochem., 66, 261, 10.1002/bab.1707
Seo, 2019, Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma, Biomaterials., 201, 87, 10.1016/j.biomaterials.2019.02.016
Sippl, 2019, MiRNA-181d expression significantly affects treatment responses to carmustine wafer implantation, Neurosurgery., 85, 147, 10.1093/neuros/nyy214
Chen, 2018, Upregulation of miR-125b, miR-181d, and miR-221 predicts poor prognosis in MGMT promoter-unmethylated glioblastoma patients, Am J Clin Pathol., 149, 412, 10.1093/ajcp/aqy008
Cardoso, 2019, MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy, Hum Mol Genet., 28, 2738, 10.1093/hmg/ddz099
Yang, 2018, MiR-29a-mediated CD133 expression contributes to cisplatin resistance in CD133+ glioblastoma stem cells, J. Mol. Neurosci., 66, 369, 10.1007/s12031-018-1177-0
Zhao, 2019, MicroRNA-29a activates a multi-component growth and invasion program in glioblastoma, J Exp Clin Cancer Res., 38, 36, 10.1186/s13046-019-1026-1
Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science., 321, 1807, 10.1126/science.1164382
Jiao, 2012, Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas, Oncotarget., 3, 709, 10.18632/oncotarget.588
Cairncross, 2014, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J Clin Oncol., 32, 783, 10.1200/JCO.2013.49.3726
Lasorella, 2017, FGFR-TACC gene fusions in human glioma, Neuro Oncol., 19, 475, 10.1093/neuonc/now240
Cahoy, 2008, A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function, J Neurosci., 28, 264, 10.1523/JNEUROSCI.4178-07.2008
Martinez, 2010, Different molecular patterns in glioblastoma multiforme subtypes upon recurrence, J Neurooncol., 96, 321, 10.1007/s11060-009-9967-4
Halliday, 2014, In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift, Proc Natl Acad Sci USA., 111, 5248, 10.1073/pnas.1321014111
Stark, 2003, p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme, J Neurol Neurosurg Psychiatry., 74, 779, 10.1136/jnnp.74.6.779
Shinsato, 2013, Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma, Oncotarget., 4, 2261, 10.18632/oncotarget.1302
Kim, 2015, Spatiotemporal evolution of the primary glioblastoma genome, Cancer Cell., 28, 318, 10.1016/j.ccell.2015.07.013
Sottoriva, 2013, Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics, Proc Natl Acad Sci USA., 110, 4009, 10.1073/pnas.1219747110
Muscat, 2018, The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection, Oncotarget., 9, 7844, 10.18632/oncotarget.23541
Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med., 352, 997, 10.1056/NEJMoa043331
Klughammer, 2018, The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space, Nat Med., 24, 1611, 10.1038/s41591-018-0156-x
Carroll, 2011, Complement in health and disease, Adv Drug Deliv Rev., 63, 965, 10.1016/j.addr.2011.06.005
Whaley, 1997, Complement and complement deficiencies, Semin Liver Dis., 17, 297, 10.1055/s-2007-1007206
Thurman, 2006, The central role of the alternative complement pathway in human disease, J Immunol, 176, 1305, 10.4049/jimmunol.176.3.1305
Daha, 1976, C3 requirements for formation of alternative pathway C5 convertase, J Immunol., 117, 630, 10.4049/jimmunol.117.2.630
Gigli, 1979, Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator, Proc Natl Acad Sci USA., 76, 6596, 10.1073/pnas.76.12.6596
Wallis, 2007, Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway, J Biol Chem., 282, 7844, 10.1074/jbc.M606326200
Heja, 2012, Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2, Proc Natl Acad Sci USA., 109, 10498, 10.1073/pnas.1202588109
Afshar-Kharghan, 2017, The role of the complement system in cancer, J Clin Invest., 127, 780, 10.1172/JCI90962
Fornvik, 2017, C1-inactivator is upregulated in glioblastoma, PLoS ONE., 12, e0183086, 10.1371/journal.pone.0183086
Junnikkala, 2000, Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1, J Immunol., 164, 6075, 10.4049/jimmunol.164.11.6075
Maenpaa, 1996, Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas, Am J Pathol., 148, 1139
Kopp, 2012, Factor H: a complement regulator in health and disease, and a mediator of cellular interactions, Biomolecules., 2, 46, 10.3390/biom2010046
Rodríguez de Córdoba, 2004, The human complement factor H: functional roles, genetic variations and disease association, Mol Immunol., 41, 355, 10.1016/j.molimm.2004.02.005
Hellwage, 1999, Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin, FEBS Lett., 462, 345, 10.1016/S0014-5793(99)01554-9
Ferreira, 2010, Complement control protein factor H: the good, the bad, and the inadequate, Mol Immunol., 47, 2187, 10.1016/j.molimm.2010.05.007
Qi, 2016, IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma, Oncotarget., 7, 71673, 10.18632/oncotarget.12317
Wang, 2004, Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells, Nat Med., 10, 48, 10.1038/nm976
Matsumura, 2007, Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells, J Immunol., 179, 2170, 10.4049/jimmunol.179.4.2170
Wesolowska, 2008, Microglia-derived TGF-beta as an important regulator of glioblastoma invasion–an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor, Oncogene., 27, 918, 10.1038/sj.onc.1210683
Ye, 2012, Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway, J Immunol., 189, 444, 10.4049/jimmunol.1103248
Fontana, 1991, Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection?, Ciba Found Symp., 157, 232, 10.1002/9780470514061.ch15
Matsushita, 2006, Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ, Cancer Sci., 97, 57, 10.1111/j.1349-7006.2006.00137.x
Crane, 2012, Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy, Neuro Oncol., 14, 584, 10.1093/neuonc/nos014
Liu, 2010, IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines, J Neurooncol., 100, 165, 10.1007/s11060-010-0158-0
Lamano, 2019, Glioblastoma-Derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth, Clin Cancer Res., 25, 3643, 10.1158/1078-0432.CCR-18-2402
Coniglio, 2012, Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling, Mol Med., 18, 519, 10.2119/molmed.2011.00217
De, 2016, CSF1 overexpression promotes high-grade Glioma formation without impacting the polarization status of glioma-associated microglia and macrophages, Cancer Res., 76, 2552, 10.1158/0008-5472.CAN-15-2386
Wu, 2010, Glioma cancer stem cells induce immunosuppressive macrophages/microglia, Neuro Oncol., 12, 1113, 10.1093/neuonc/noq082
DeCordova, 2019, Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma multiforme patients, Immunobiology., 224, 625, 10.1016/j.imbio.2019.07.006
Badie, 2001, Expression of Fas ligand by microglia: possible role in glioma immune evasion, J Neuroimmunol., 120, 19, 10.1016/S0165-5728(01)00361-7
Pangburn, 2008, Discrimination between host and pathogens by the complement system, Vaccine., 26, 15, 10.1016/j.vaccine.2008.11.023
Schmidt, 2017, Protection of host cells by complement regulators, Immunol Rev., 274, 152, 10.1111/imr.12475
Cho, 2015, Complement regulation: physiology and disease relevance, Korean J Pediatr., 58, 239, 10.3345/kjp.2015.58.7.239
Tegla, 2013, Membrane attack by complement: the assembly and biology of terminal complement complexes, Immunol Res., 52, 45, 10.1007/s12026-011-8239-5
Junnikkala, 2002, Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells, Br J Cancer., 87, 1119, 10.1038/sj.bjc.6600614
Ratnoff, 1957, Some properties of an esterase derived from preparations of the first component of complement, J Exp Med., 106, 327, 10.1084/jem.106.2.327
Sim, 1979, Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma, FEBS Lett., 97, 111, 10.1016/0014-5793(79)80063-0
Sim, 1980, Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s, Biochim Biophys Acta., 612, 433, 10.1016/0005-2744(80)90126-6
Fornvik, 2018, Anti-C1-inactivator treatment of glioblastoma, Oncotarget., 9, 37421, 10.18632/oncotarget.26456
Davies, 1989, CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells, J Exp Med., 170, 637, 10.1084/jem.170.3.637
Fodor, 1995, A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex, J Immunol., 155, 4135, 10.4049/jimmunol.155.9.4135
Liszewski, 1991, Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster, Annu Rev Immunol., 9, 431, 10.1146/annurev.iy.09.040191.002243
Louveau, 2015, Revisiting the mechanisms of CNS immune privilege, Trends Immunol., 36, 569, 10.1016/j.it.2015.08.006
Bailey, 2006, Innate and adaptive immune responses of the central nervous system, Crit Rev Immunol., 26, 149, 10.1615/CritRevImmunol.v26.i2.40
Russo, 2015, Immune surveillance of the CNS following Infection and Injury, Trends Immunol., 36, 637, 10.1016/j.it.2015.08.002
Cserr, 1992, Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance, Brain Pathol., 2, 269, 10.1111/j.1750-3639.1992.tb00703.x
Mohammad, 2014, Immune cell trafficking from the brain maintains CNS immune tolerance, J Clin Invest., 124, 1228, 10.1172/JCI71544
Engelhardt, 2012, Capture, crawl, cross: the T cell code to breach the blood-brain barriers, Trends Immunol., 33, 579, 10.1016/j.it.2012.07.004
Ginhoux, 2010, Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science., 330, 841, 10.1126/science.1194637
Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science, 308, 1314, 10.1126/science.1110647
Ajami, 2011, Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool, Nat Neurosci., 14, 1142, 10.1038/nn.2887
Casano, 2015, Microglia: multitasking specialists of the brain, Dev Cell., 32, 469, 10.1016/j.devcel.2015.01.018
Hickey, 1988, Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo, Science., 239, 290, 10.1126/science.3276004
Perng, 2015, Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites, Front Oncol., 5, 153, 10.3389/fonc.2015.00153
Badie, 2000, Flow cytometric characterization of tumor-associated macrophages in experimental gliomas, Neurosurgery., 46, 957, 10.1227/00006123-200004000-00035
Dick, 1995, Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b/c+CD4low parenchymal microglia, Br J Ophthalmol., 79, 834, 10.1136/bjo.79.9.834
Parney, 2009, Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation, J Neurosurg., 110, 572, 10.3171/2008.7.JNS08475
Muller, 2015, Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells, Int J Cancer., 137, 278, 10.1002/ijc.29379
Morantz, 1979, Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors, J Neurosurg., 50, 305, 10.3171/jns.1979.50.3.0305
Bettinger, 2002, Microglia promote glioma migration, Acta Neuropathol., 103, 351, 10.1007/s00401-001-0472-x
Markovic, 2005, Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2, J Neuropathol Exp Neurol, 64, 754, 10.1097/01.jnen.0000178445.33972.a9
Yeung, 2012, p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells, J Neurooncol, 109, 35, 10.1007/s11060-012-0875-7
Jacobs, 2012, Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia, Neuro Oncol., 14, 119, 10.1093/neuonc/nor194
Burns, 2006, A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development, J Exp Med., 203, 2201, 10.1084/jem.20052144
Rempel, 2000, Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma, Clin Cancer Res., 6, 102
Salmaggi, 2004, CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells, J Neuro Oncol., 67, 305, 10.1023/B:NEON.0000024241.05346.24
Chang, 2016, CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells, Cancer Res., 76, 5671, 10.1158/0008-5472.CAN-16-0144
Bowman, 2014, Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma, Immunotherapy., 6, 663, 10.2217/imt.14.48
Hambardzumyan, 2016, The role of microglia and macrophages in glioma maintenance and progression, Nat Neurosci., 19, 20, 10.1038/nn.4185
Takeshima, 1994, Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma, J Neurosurg., 80, 1056, 10.3171/jns.1994.80.6.1056
Zhu, 2011, Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy, J Neuro Oncol., 104, 83, 10.1007/s11060-010-0473-5
Platten, 2001, Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape, Microsc Res Tech., 52, 401, 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C
Wang, 2012, Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model, Lab Invest., 92, 151, 10.1038/labinvest.2011.128
Bao, 2019, High glucose promotes human glioblastoma cell growth by increasing the expression and function of chemoattractant and growth factor receptors, Transl Oncol., 12, 1155, 10.1016/j.tranon.2019.04.016
Wei, 2019, Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target, J Clin Invest, 129, 137, 10.1172/JCI121266
Friedberg, 1998, Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis, Cancer., 82, 923, 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2
Belien, 1999, Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter, J Cell Biol., 144, 373, 10.1083/jcb.144.2.373
Du, 2008, Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM, Neuro Oncol., 10, 254, 10.1215/15228517-2008-001
Markovic, , Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion, Proc Natl Acad Sci USA., 106, 12530, 10.1073/pnas.0804273106
van Meir, 1995, Cytokines and tumors of the central nervous system, Glia., 15, 264, 10.1002/glia.440150308
Nduom, 2015, Immunosuppressive mechanisms in glioblastoma, Neuro Oncol., 17, vii9, 10.1093/neuonc/nov151
Liau, 1999, Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens, J Neurosurg., 90, 1115, 10.3171/jns.1999.90.6.1115
Pellegatta, 2006, Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice, Neurol Res., 28, 527, 10.1179/016164106X116809
Liau, 2005, Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment, Clin Cancer Res., 11, 5515, 10.1158/1078-0432.CCR-05-0464
Yu, 2001, Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration, Cancer Res., 61, 842
Liau, 2018, First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma, J Transl Med., 16, 142, 10.1186/s12967-018-1507-6
Friese, 2004, RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo, Cancer Res., 64, 7596, 10.1158/0008-5472.CAN-04-1627
Tran, 2007, Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model, Neuro Oncol., 9, 259, 10.1215/15228517-2007-010
Sivori, 2000, Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines, J Neuroimmunol., 107, 220, 10.1016/S0165-5728(00)00221-6
Castriconi, 2009, NK cells recognize and kill human glioblastoma cells with stem cell-like properties, J Immunol., 182, 3530, 10.4049/jimmunol.0802845
Lee, 2015, Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain, BMC Cancer., 15, 1011, 10.1186/s12885-015-2034-y
Ooi, 2014, The role of regulatory T-cells in glioma immunology, Clin Neurol Neurosurg., 119, 125, 10.1016/j.clineuro.2013.12.004
Allan, 2005, The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs, J Clin Invest., 115, 3276, 10.1172/JCI24685
Colombo, 2007, Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy, Nat Rev Cancer., 7, 880, 10.1038/nrc2250
Jacobs, 2010, Prognostic significance and mechanism of Treg infiltration in human brain tumors, J Neuroimmunol., 225, 195, 10.1016/j.jneuroim.2010.05.020
Heimberger, 2008, Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas, Clin Cancer Res., 14, 5166, 10.1158/1078-0432.CCR-08-0320
Elliott, 1987, Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas, J Neurosurg., 67, 231, 10.3171/jns.1987.67.2.0231
Humphries, 2010, The role of tregs in glioma-mediated immunosuppression: potential target for intervention, Neurosurg Clin N Am., 21, 125, 10.1016/j.nec.2009.08.012
Jordan, 2008, Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy, Cancer Immunol Immunother., 57, 123, 10.1007/s00262-007-0336-x
Desbaillets, 1994, Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro, Int J Cancer., 58, 240, 10.1002/ijc.2910580216
Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell., 27, 450, 10.1016/j.ccell.2015.03.001
Bloch, 2013, Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages, Clin Cancer Res., 19, 3165, 10.1158/1078-0432.CCR-12-3314
Liang, 2003, Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses, Eur J Immunol., 33, 2706, 10.1002/eji.200324228
Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer., 12, 252, 10.1038/nrc3239
Wei, 2014, The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression, Tumour Biol., 35, 2923, 10.1007/s13277-013-1376-9
Parsa, 2007, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nat Med., 13, 84, 10.1038/nm1517
Zeng, 2013, Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas, Int J Radiat Oncol Biol Phys., 86, 343, 10.1016/j.ijrobp.2012.12.025
Fecci, 2007, Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function, Clin Cancer Res., 13, 2158, 10.1158/1078-0432.CCR-06-2070
McGranahan, 2019, Current state of immunotherapy for treatment of glioblastoma, Curr Treat Options Oncol., 20, 24, 10.1007/s11864-019-0619-4
Caccese, 2019, PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review, Crit Rev Oncol Hematol., 135, 128, 10.1016/j.critrevonc.2018.12.002
Arrieta, 2019, Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?, J Neurosurg., 132, 1, 10.3171/2019.9.JNS192523
Adhikaree, 2020, Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma, Cells., 9, 263, 10.3390/cells9020263
Batich, 2017, Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination, Clin Cancer Res., 23, 1898, 10.1158/1078-0432.CCR-16-2057
Nair, 2014, Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells, Clin Cancer Res., 20, 2684, 10.1158/1078-0432.CCR-13-3268
Mitchell, 2015, Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients, Nature., 519, 366, 10.1038/nature14320
Eisenstein, 2018, Immunotherapy offers a promising bet against brain cancer, Nature., 561, S42, 10.1038/d41586-018-06705-6
ORourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med., 9, eaaa0984, 10.1126/scitranslmed.aaa0984
Johnson, 2015, Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma, Sci Transl Med., 7, 275ra22, 10.1126/scitranslmed.aaa4963
Jackson, 2015, Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target, Carcinogenesis., 36, 177, 10.1093/carcin/bgu243
Audia, 2017, The impact of the tumor microenvironment on the properties of glioma stem-like cells, Front Oncol., 7, 143, 10.3389/fonc.2017.00143
Yang, 2020, MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway, Oncogene., 39, 1098, 10.1038/s41388-019-1045-6
Ricklefs, 2018, Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles, Sci Adv., 4, eaar2766, 10.1126/sciadv.aar2766
Facoetti, 2005, Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors, Clin Cancer Res., 11, 8304, 10.1158/1078-0432.CCR-04-2588
Zhou, 2015, Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth, Nat Cell Biol., 17, 170, 10.1038/ncb3090
Raychaudhuri, 2011, Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma, Neuro Oncol., 13, 591, 10.1093/neuonc/nor042
Raychaudhuri, 2015, Myeloid derived suppressor cell infiltration of murine human gliomas is associated with reduction of tumor infiltrating lymphocytes, J Neurooncol., 122, 293, 10.1007/s11060-015-1720-6
Dubinski, 2016, CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients, Neuro Oncol, 18, 807, 10.1093/neuonc/nov280
Di Tomaso, 2010, Immunobiological characterization of cancer stem cells isolated from glioblastoma patients, Clin Cancer Res, 16, 800, 10.1158/1078-0432.CCR-09-2730
Kamran, 2017, Immunosuppressive myeloid cells' blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy, Mol Ther., 25, 232, 10.1016/j.ymthe.2016.10.003
Otvos, 2016, Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion, Stem Cells, 34, 2026, 10.1002/stem.2393
Wei, 2010, Glioma-associated cancer-initiating cells induce immunosuppression, Clin Cancer Res, 16, 461, 10.1158/1078-0432.CCR-09-1983
Chen, 2017, Cellular and molecular identity of tumor-associated macrophages in glioblastoma, Cancer Res, 77, 2266, 10.1158/0008-5472.CAN-16-2310
Fujita, 2011, COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells, Cancer Res., 71, 2664, 10.1158/0008-5472.CAN-10-3055
Alban, 2018, Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis, JCI Insight, 3, e122264, 10.1172/jci.insight.122264
Umemura, 2008, Tumor- infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics, J Leukoc Biol, 83, 1136, 10.1189/jlb.0907611